Global Transdermal Patch Market and Clinical Pipeline Outlook 2022

January 11th, 2018 Releases

Facebook Twitter Google+ LinkedIn

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-transdermal-patch-market-and-clinical-pipeline-outlook-2022.php

 

Table of Contents

 

  1. Introduction to Transdermal Patch
  1. Classification of Transdermal Patches
  2.1 Single/ Multiple-Layer Drug-in-Adhesive
  2.2 Reservoir Transdermal Patches
  2.3 Matrix Based Transdermal Patches
  2.4 Vapor Patch
  2.5 Active and Passive Patch
  1. Why There Exist Need for Transdermal Patches?
  1. Mechanism of Transdermal Patch Drug Delivery
  4.1 Properties of Transdermal Therapeutics
  4.2 Components of Transdermal Patch
  4.3 Mechanism of Motion Sickness, Nicotine and Female Contraceptive Transdermal Patch
  1. Transdermal Patch v/s Traditional Drug Delivery Methods
  1. Global Transdermal Patch Market Outlook
  6.1 Global Market Scenario
  6.2 Regional Trends
  1. Global Transdermal Patch Clinical Pipeline Overview
  7.1 By Phase
  7.2 By Region/Country
  7.3 By Drug Class/Molecule
  7.4 By Company
  7.5 By Orphan and Fast Track Status
  7.6 By Mode of Action
  1. Global Transdermal Patch Market Dynamics
  8.1 Favorable Market Parameters
  8.2 Commercialization Challenges
  1. Global Transdermal Patch Market Future Prospects
  1. Global Transdermal Patch Clinical Insight
  10.1 Unknown
  10.2 Research
  10.3 Preclinical
  10.4 Clinical
  10.5 Phase-I
  10.6 Phase-I/II
  10.7 Phase-II
  10.8 Phase-II/III
  10.9 Phase-III
  10.10 Preregistration
  10.11 Registered
  1. Marketed Transdermal Patch Clinical Insight by Company, Indication and Phase
  1. Competitive Landscape
  12.1 3M Pharmaceuticals
  12.2 Acrux
  12.3 Agile Therapeutics
  12.4 Allergan
  12.5 ANI Pharmaceuticals
  12.6 Antares Pharma
  12.7 Bayer HealthCare Pharmaceuticals
  12.8 Corium International
  12.9 Chase Pharmaceuticals
  12.10 DURECT Corporation
  12.11 Endo Pharmaceuticals
  12.12 Fempharm
  12.13 Hisamitsu Pharmaceutical
  12.14 Immune Pharmaceuticals
  12.15 Imprimis Pharmaceuticals
  12.16 Ipsen Bioscience
  12.17 Johnson and Johnson
  12.18 LaSalle Laboratories
  12.19 Lavipharm-increase
  12.20 MINRAD International
  12.21 NeurogesX
  12.22 Noven Pharmaceuticals
  12.23 NuPathe
  12.24 Nuvo Research
  12.25 Novartis
  12.26 Pain Therapeutics
  12.27 ProStrakan
  12.28 Purdue Pharma
  12.29 Sanofi
  12.30 Scilex Pharmaceuticals
  12.31 Senju Pharmaceutical
  12.32 Somerset Pharmaceuticals
  12.33 Teikoku Seiyaku
  12.34 Therapeutic Discovery Corporation
  12.35 Transdermal Delivery Solutions Corp
  12.36 UCB-full form
  12.37 Xel Pharmaceuticals
  12.38 Zosano Pharma

 

Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal  Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Global andndash; Transdermal Patch Market Opportunity (US$ Billion), 2016-2022
Figure 7-1: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-2: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-3: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-4: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-5: Global – Transdermal Patch Pipeline by Region (%), 2017 till 2022
Figure 7-6: Global – Transdermal Patch Pipeline by Country (%), 2017 till 2022
Figure 7-7: Global – Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022
Figure 7-8: Global – Transdermal Patch Pipeline by Company (%), 2017 till 2022
Figure 7-9: Global – Transdermal Patch Pipeline by Ophan and Fast Track Status (%), 2017 till 2022
Figure 7-10: Global – Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022
Figure 8-1: Drivers for Transdermal Patch
Figure 8-2: Transdermal Patch Market Commercialization Challenges
Figure 12-1: Acrux Clinical Pipeline
Figure 12-2: Agile Therapeutics Clinical Pipeline
Figure 12-3: Antares Pharma Clinical Pipeline
Figure 12-4: Corium International Clinical Pipeline
Figure 12-5: Durect Corporation Clinical Pipeline
Figure 12-6: Endo Pharmaceuticals Clinical Pipeline
Figure 12-7: Immune Pharmaceuticals Clinical Pipeline
Figure 12-8: Novartis Clinical Pipeline
Figure 12-9: Senju Pharmaceuticals Clinical Pipeline
Figure 12-10: Xel Pharamaceuticals Clinical Pipeline
Figure 12-11: Zosano Pharma Clinical Pipeline

 

 

Table 2-1: Differences between Active and Passive Transdermal Patches
Table 4-1: Transdermal Patches for Various Disease Indications
Table 12-1: Pain Therapeutics Clinical Pipeline

 

© Medgadget, LLC. 2004-2018. All rights reserved. | The Medical Revolution Will Be Blogged.

MED TECH THAT TRANSFORMS THE WORLD

Exclusive Medgadget news in your mailbox!

Your information will never be shared with any third party.

X